-
"Diversity, Equity and Inclusion" Page Renewal
Introducing Eisai DE&I: Now and the Future
Learn more
"Diversity, Equity and Inclusion" Page Renewal
Introducing Eisai DE&I: Now and the Future
-
Looking Back on 10 Years Since the Commencement of Free Provision of DEC Tablets
Eisai Staff in Charge Talks About Overcoming Challenges on the Uneven Road by Building Trust in Global Partnerships
-
Scientists Discuss the Development of a New Treatment for the Elimination of Mycetoma
-
New Innovation Page Launch
-
July 26, 2024
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
-
July 24, 2024
-
July 23, 2024
-
July 16, 2024
EISAI ENTERS INTO LICENSE AGREEMENT FOR FOSRAVUCONAZOLE IN ASIA/OCEANIA WITH SATO PHARMA
-
July 12, 2024
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Israel
-
July 11, 2024
-
July 3, 2024
-
June 17, 2024
IR "Notice of Shareholder Voting Results for the 112th Ordinary General Meeting of Shareholders"
-
June 17, 2024
-
June 14, 2024
IR "Notice of Resolution of the 112th Ordinary General Meeting of Shareholders"
-
June 21, 2024
Notification Regarding Revision of “Eisai Global Code of Conduct for Business Partners”
-
June 3, 2024
The Naito Museum of Pharmaceutical Science and Industry Listed as “Registered Museum”
-
April 8, 2024
-
October 13, 2023
-
March 9, 2023
Warning Against Solicitation, Fraudulent Emails, etc. that Use the Name of Eisai or Related Parties
Sustainability
30 countries 2.28 billion tablets
Number of countries supplied with lymphatic filariasis treatment
and volume supplied (as of March 2024)
Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries